Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Tinlarebant has previously been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A density gradient of basement membrane laminins modulates retinal pigment epithelium contractility levels by differential ...

Biomedical engineers at Duke University have developed a novel imaging system that harnesses the power of artificial ...

New research reveals a retinal light test may hold the key to detecting Parkinson's disease long before motor symptoms appear ...

Durham-based Atsena Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ATSN-201, its gene therapy product for the ...

Background Coronary artery disease (CAD) is linked to an increased risk of mild cognitive impairment (MCI). Effective and ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of ...

Scientists say they have determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nutrients, waste and ...